Table 1 Age, sex distribution, outcome, comorbidities, symptoms, and chest x-ray of the studied group
Frequency | Percent | |
|---|---|---|
Sex | ||
Male | 124 | 56.4 |
Female | 96 | 43.6 |
Age | ||
Mean±SD | 67.1±11.48 | |
Median | 68 | |
Range | 40–107 | |
Outcomes | ||
Improved | 177 | 80.5 |
Deteriorated | 43 | 19.5 |
SOB after sotrovimab | ||
Improved | 177 | 80.5 |
Deteriorated | 43 | 19.5 |
Cough after sotrovimab | ||
Improved | 177 | 80.5 |
Deteriorated | 43 | 19.5 |
CXR after sotrovimab | ||
Improved | 177 | 80.5 |
Deteriorated | 43 | 19.5 |
Hospitalization after sotrovimab (primary outcome) | ||
Hospitalized | 41 | 18.6 |
Not hospitalized | 179 | 81.4 |
Comorbidities | ||
DM | ||
No | 129 | 58.6 |
Yes | 91 | 41.4 |
HTN | ||
No | 121 | 55.0 |
Yes | 99 | 45.0 |
CKD | ||
No | 184 | 83.6 |
Yes | 36 | 16.4 |
Asthma | ||
No | 202 | 91.8 |
Yes | 18 | 8.2 |
Hypothyroidism | ||
No | 210 | 95.5 |
Yes | 10 | 4.5 |
IHD | ||
No | 181 | 82.3 |
Yes | 39 | 17.7 |